Understanding ARCN1: Potential Drug Target Or Biomarker for Neurodegenerative Diseases

Target Name: ARCN1

NCBI ID: G372

ARCN1

Understanding ARCN1: Potential Drug Target Or Biomarker for Neurodegenerative Diseases

ARCN1 (Aspartic Acid Repeat-Containing Nuclear Protein 1) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidney. It is characterized by the presence of an arginine residue in its amino acid sequence , which is a modified form of arginine that can interact with various molecules in the body.

The ARCN1 protein is involved in a number of cellular processes that are important for normal cellular function. One of its functions is to act as a regulator of the cell cycle, helping to control the entry and exit of cells into the cell cycle. This protein is also involved in the regulation of cell growth, and has been shown to play a role in the development and progression of various diseases, including cancer.

In addition to its role in cell regulation, ARCN1 has also been shown to be involved in the development and progression of neurodegenerative diseases. Studies have shown that ARCN1 is expressed in the brains of individuals with Alzheimer's disease, and that its levels are increased in individuals with Parkinson's disease. Additionally, ARCN1 has been shown to be involved in the development of neurofibrillary tangles, a hallmark of neurodegenerative diseases, in both humans and animal models.

Despite these promising findings, more research is needed to fully understand the role of ARCN1 in neurodegenerative diseases. One potential approach to studying ARCN1 is to use it as a drug target or biomarker. By targeting ARCN1 with small molecules or other compounds, researchers may be able to interfere with its function and study its effects on neurodegenerative diseases. This could lead to the development of new treatments for these debilitating conditions.

Another approach to studying ARCN1 is to use it as a sample to study the effects of drugs on neurodegenerative diseases. By analyzing the levels and distribution of ARCN1 in the brain, researchers may be able to study how different drugs affect the expression and function of this protein. This could provide valuable information about the mechanisms underlying neurodegenerative diseases and the potential development of new treatments.

In conclusion, ARCN1 is a protein that is expressed in various tissues of the body and is involved in a number of cellular processes that are important for normal cellular function. Its role in the development and progression of neurodegenerative diseases makes it an attractive target for research and treatment. Further research is needed to fully understand the role of ARCN1 in these conditions, and to develop new treatments for these debilitating diseases.

Protein Name: Archain 1

Functions: Component of the coatomer, a cytosolic protein complex that binds to dilysine motifs and reversibly associates with Golgi non-clathrin-coated vesicles, which further mediate biosynthetic protein transport from the ER, via the Golgi up to the trans Golgi network. The coatomer complex is required for budding from Golgi membranes, and is essential for the retrograde Golgi-to-ER transport of dilysine-tagged proteins. In mammals, the coatomer can only be recruited by membranes associated to ADP-ribosylation factors (ARFs), which are small GTP-binding proteins; the complex also influences the Golgi structural integrity, as well as the processing, activity, and endocytic recycling of LDL receptors (By similarity)

The "ARCN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARCN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets